Pedro A Hermida de Viveiros, MD serves as an Assistant Professor in the Department of Medicine, Division of Hematology and Oncology at Northwestern University's Feinberg School of Medicine. His clinical practice focuses on solid tumor oncology with specialized expertise in sarcomas and precision medicine approaches. His research interests center on clinical development of novel therapeutic strategies for sarcomas and gastrointestinal stromal tumors (GIST), emphasizing biomarker-driven treatments and molecularly targeted therapies. Key areas include IDH1-mutant chondrosarcoma management, neoadjuvant response assessment in sarcomas, and immunotherapy-radiotherapy combinations for metastatic disease. Analysis of his recent publications reveals a consistent focus on translating molecular targets into clinical applications, particularly through phase 1-3 trials of targeted agents like ivosidenib and IDRX-42. His work bridges radiological assessment, pathological response, and precision oncology frameworks for rare solid tumors. Professional engagements include active membership in major oncology societies: American Society of Clinical Oncology (ASCO) Connective Tissue Oncology Society (CTOS) Sociedade Brasileira de Oncologia Clínica (SBOC) European Society for Medical Oncology (ESMO) He currently leads four active clinical trials through the Robert H. Lurie Comprehensive Cancer Center, including the CHONQUER phase 3 study of ivosidenib for IDH1-mutant chondrosarcoma and first-in-human trials of novel agents for advanced solid tumors and GIST. His work integrates translational research with clinical trial design to advance personalized treatment paradigms.
Professor Ananya Choudhury serves as Chair and Honorary Consultant in Clinical Oncology at the University of Manchester, where she is also Co-Group Leader of the Translational Radiobiology Group within the Division of Cancer Sciences. She joined The Christie NHS Foundation Trust in 2008, specializing in urology and sarcoma, and has since focused on radiotherapy-related research in prostate and bladder cancers. Professor Choudhury is clinical lead for advanced radiotherapy, including the groundbreaking MRLinac project, and plays a key role in national radiotherapy research initiatives. Professor Choudhury earned her BA (Hons) in 1993, MB. BChir (Cantab) in 1995, and MA (Cantab) in 1997 from Trinity College, Cambridge. She completed her Clinical Oncology training at the Yorkshire Deanery from 2000-2008, during which she earned her MRCP in 2000 and F.R.C.R in 2004. She completed her PhD in 2008 through the University of Leeds and Princess Margaret Hospital in Toronto, Canada, where she studied the molecular epidemiology of DNA double strand break repair in bladder cancer. Professor Choudhury's research program focuses on optimizing and personalizing radiotherapy using advanced imaging technology to deliver high doses while minimizing side effects. Her work centers on prostate and bladder cancers, with particular interest in predictive biomarkers, hypoxia, and the integration of magnetic resonance imaging to improve treatment precision. She has pioneered research in radiotherapy dose optimization, biomarker development, and the identification of patients who would benefit most from different treatment approaches. Her extensive publication record demonstrates a strong focus on radiation therapy, particularly in genitourinary cancers. Recent work explores MRI-guided radiotherapy, hypoxia biomarkers, and personalized treatment approaches across multiple cancer types. She has made significant contributions to understanding how imaging technology can improve radiotherapy precision and effectiveness while reducing side effects, with several publications appearing in top journals through 2025. Professor Choudhury has received multiple prestigious awards recognizing her contributions to the field: Cancer Research-UK/Royal College of Radiologists Clinical Training Fellowship (2005) Fellowship for the 10th ECCO-AACR-ASCO Workshop on Methods in Clinical Cancer Research (2007) Outstanding Contribution, Greater Manchester Clinical Research Awards (2017) RCR Research Fellowship (2005) Research Fellowship, Princess Margaret Hospital, Toronto (2004) Professor Choudhury has supervised numerous doctoral and master's students across multiple cancer types, with current students expected to complete through 2024. She is Principal Investigator on multiple research grants, including 'Measuring tumour radioresistance to improve radiotherapy outcomes' and the 'MAESTRO Programme' as part of CRUK RadNet. Her research program is supported by significant funding from NIHR Manchester Biomedical Research Centre and other major funding bodies. As Co-Group Leader of the Translational Radiobiology Group, Professor Choudhury collaborates extensively with leading researchers including Peter Hoskin, Catharine West, Corinne Faivre-Finn, and Marcel van Herk. Her team is at the forefront of integrating advanced imaging with radiotherapy to improve cancer treatment outcomes, with active projects spanning from basic radiobiology to clinical implementation of novel radiotherapy techniques.
University of North Carolina at Chapel HillUnited States
Xiaodong Wang is a Professor at the Center for Integrative Chemical Biology and Drug Discovery within the Eshelman School of Pharmacy at the University of North Carolina at Chapel Hill. His research program focuses on developing innovative drug leads and candidates targeting novel protein kinases and other molecular targets identified by UNC faculty and external investigators. Dr. Wang's research interests center on structure- and ligand-based drug design approaches for developing therapeutic compounds, particularly kinase inhibitors targeting the TAM family (TYRO3, AXL, MERTK). His laboratory has successfully applied these methodologies to deliver compounds to clinical trials, including MerTK inhibitors and IDH1 inhibitors developed in collaboration with NCATS. Current research continues to focus on structure-based drug design for novel targets, with particular emphasis on cancer therapeutics and molecular imaging agents. Analysis of Dr. Wang's recent publications (2023-2025) reveals a strong focus on developing selective kinase inhibitors, particularly targeting the TAM receptor family (TYRO3, AXL, MERTK) for various cancer types including leukemia, Ewing sarcoma, and melanoma. His work spans multiple disciplines including medicinal chemistry, cancer biology, immunology, and molecular imaging, with recent publications appearing in high-impact journals such as Journal of Medicinal Chemistry, Nature Communications, and Leukemia. Dr. Wang maintains active collaborations across UNC-Chapel Hill and with external institutions, working with researchers in pharmacology, oncology, immunology, and structural biology. His laboratory develops both small molecule inhibitors and imaging agents, with several compounds progressing toward clinical applications. Contact information: xiaodonw@email.unc.edu | Wang Lab website
Lieuwke Kranenburg is an Assistant Professor at the Faculty of Veterinary Medicine , Utrecht University , specializing in Equine Internal Medicine . She provides patient care at the University Equine Clinic and teaches Master's courses in equine digestion , infectious diseases , and skin problems . Research Focus: Equine internal medicine, digestive diseases, infectious pathogens, metabolic disorders Professional Certifications: EBVS® European Veterinary Specialist in Equine Internal Medicine International Collaboration: Trained Chinese veterinarians at Heilan Equestrian Centre Publications highlight her work on equine gastric disease management, diagnostic imaging, infectious disease epidemiology, and metabolic research. She contributes to equine clinical research through peer-reviewed journals and conference abstracts. Professional Involvement: Former board member of the Equine Medicine Group and current GGP representative for FEEVA, maintaining professional networks and advancing equine veterinary practice.
Brane Grambozov is a Clinical Professor in the Department of Radiotherapy and Radiation Oncology at the Medical University of Vienna. His research focuses on oncology, radiation therapy, and immunotherapy, particularly in lung cancer treatment and molecular mechanisms of non-small cell lung cancer (NSCLC). He has contributed to studies on Durvalumab's impact on survival outcomes and radiation dose escalation strategies in NSCLC Stage III patients through the Austrian Radio-Oncological Lung Cancer Study Association Registry (ALLSTAR). Education: Not explicitly stated. Research interests include immunotherapy efficacy, radiation dosimetry, and biomarkers in oncology. His work emphasizes clinical trials and real-world data analysis to improve treatment outcomes and reduce toxicities like pneumonitis. He has collaborated with teams like the ALLSTAR Group and contributed to interdisciplinary studies involving radiotherapy planning and molecular biology. Key awards include the 2022 Platz Research Prize from the Austrian Society for Radiation Oncology. His advising/grant activities are not detailed but reflect contributions to lung cancer research through institutional and collaborative efforts. Labs/teams: Collaborations with the ALLSTAR Group and involvement in multidisciplinary oncology research networks.
Andrew T Arndt, MD is a Clinical Assistant Professor in the Department of Surgery specializing in Thoracic Surgery at Northwestern University's Feinberg School of Medicine. Board certified by the American Board of Thoracic Surgery, he maintains clinical practice at Northwestern Medicine Central DuPage Hospital and holds active memberships in the Society of Thoracic Surgeons (2023-present) and American Board of Thoracic Surgery (2022-present). His research concentrates on advancing thoracic surgical oncology through investigations into lung cancer resection outcomes, chest wall tumor management, minimally invasive techniques, and pneumothorax recurrence factors. Current work emphasizes evidence-based risk stratification and surgical innovation to improve patient outcomes in complex thoracic pathologies. Recent publications demonstrate consistent focus on surgical registry analysis (2021), consensus development for thoracoscopic training (2021), systematic reviews of rare chest wall malignancies (2023), and identification of lifestyle-related recurrence risks (2021). This trajectory highlights growing contributions to thoracic surgical guidelines and evidence-based practice standards. Dr. Arndt serves as a consultant for Intuitive Surgical, Inc. (2024 disclosures) while maintaining active clinical and academic roles. No formal advisees or research grants are listed in current profile materials. Within Northwestern's Department of Surgery, he contributes to the Thoracic Surgery division's clinical and research missions, particularly in advancing minimally invasive approaches and multidisciplinary management of complex thoracic conditions through collaborative registry studies and consensus initiatives.
Xiaofeng Liu is an Assistant Professor at Yale University School of Medicine in the Departments of Radiology & Biomedical Imaging and Biomedical Informatics & Data Science. He is also an Associate Member at the Broad Institute of MIT and Harvard. Previously, he held faculty positions at Harvard Medical School and research roles at Massachusetts General Hospital and Beth Israel Deaconess Medical Center. PhD in Mechatronics from University of Chinese Academy of Sciences Dual Bachelor's degrees in Automation (Wang-Daheng Elite Class) and Communication from University of Science and Technology of China His research integrates trustworthy AI, medical imaging, and data science to improve diagnosis, prognosis, and treatment monitoring for neurological disorders, cancer, and cardiovascular diseases. Key focus areas include domain adaptation techniques, diffusion models, and interpretable AI systems. Led special issues in IEEE Transactions on Pattern Analysis and Medical Image Analysis Developed novel frameworks like Ordinal UDA and Memory-Consistent Adaptation Scientific accolades include the Trailblazer R21 Award (NIBIB), OpenAI Research Award, and National Artificial Intelligence Research Resource Pilot Award. He serves as Associate Editor for IEEE Transactions on Neural Networks and Learning Systems and actively contributes to MICCAI and NIH review panels. His lab at Yale (XLiu Lab) investigates neural basis of intelligence to inspire AI development, with applications in brain tumor segmentation, cardiac imaging, and cross-modal medical diagnostics.
Prim. Clin. Assoc. Prof. PD Dr. Dietmar Dammerer, MSc PhD is the head of the Clinical Department of Orthopaedics and Traumatology at Krems University Hospital, affiliated with Karl Landsteiner Private University of Health Sciences. He has been in this role since February 2022, leading the merger of orthopedics and traumatology into a unified clinical department. A dual-trained specialist, he is recognized for his expertise in endoprosthetics and tumor orthopedics, and actively promotes interdisciplinary collaboration and team-based medicine. His educational background includes a PhD in Musculoskeletal Sciences (2015), an MSc in Advanced Orthopaedics and Traumatology (2017), and board certification in both orthopedics and traumatology (2017, 2018), culminating in habilitation in 2019. He has received prestigious Traveling Fellowships from the European Hip Society and European Musculo-Skeletal Oncology Society. Dietmar Dammerer’s research focuses on orthopedic oncology, joint reconstruction, biomechanics, and minimally invasive surgery. His work emphasizes the integration of clinical inquiry with research to improve patient outcomes. Recent publications analyze pelvic sarcoma reconstruction, spinal metastases, cartilage repair techniques, and health disparities in sarcoma care. His 15 most recent articles reflect a strong trend in musculoskeletal oncology, surgical biomechanics, and evidence-based orthopedic practice, with frequent use of systematic reviews, retrospective studies, and multicenter collaborations. Topics include implant performance, surgical safety, and global access to specialized care. Scientific awards include: Traveling Fellow Stipendium from the European Hip Society (2018) Traveling Fellow Stipendium from the European Musculo-Skeletal Oncology Society (2020) He is deeply committed to mentoring and team development, emphasizing that medical success is measured by the success of one’s colleagues. He leads a research-active department that hosts international observers, conducts training courses for physicians across Europe, the Middle East, and Africa, and maintains a high rate of peer-reviewed publication. The department collaborates closely with the Departments of Biomechanics and Anatomy and Developmental Biology, reflecting a multidisciplinary research approach.
Professor Martin Peifer is a computational cancer genomics researcher at the University of Cologne, where he leads the Department of Translational Genomics. He serves as Principal Investigator of the Peifer Lab, which focuses on developing computational methods to analyze cancer genome sequencing data. His work is deeply integrated with the Center for Data and Simulation Science and he is an active member of the International Cancer Genome Consortium and the Pan-Cancer Analysis of Whole Genomes project. Peifer's research interests center on computational approaches to understanding cancer biology, with particular emphasis on tumor evolution and genome instability mechanisms. His lab develops methods to analyze somatic genome alterations including point mutations, copy number changes, and rearrangements. They also create computational tools for integrative genome analyses, tumor evolution reconstruction, and single-cell sequencing data analysis (both RNA and DNA). His interdisciplinary team applies high-performance computing and machine learning to interpret complex cancer sequencing data, aiming to better understand tumorigenesis, clonal evolution, and therapy resistance. Analysis of Peifer's extensive publication record reveals a strong focus on neuroblastoma and lung cancer genomics, with particular attention to tumor evolution patterns and genomic instability mechanisms. His work spans multiple cancer types but maintains consistent themes of computational methodology development and application to understand cancer progression and treatment resistance. The publications demonstrate increasing sophistication in analyzing intra-tumor heterogeneity and clonal dynamics over time. Peifer leads an active research group including postdoctoral fellows (Joel Kaufmann, Dr. Stephanie Pabel, Agnieszka Rumińska) and PhD students (Magdalena Seiffert, Justinas Valiulis). His lab is involved in the Collaborative Research Center 1399 focused on Mechanisms of Drug Sensitivity and Resistance in Small Cell Lung Cancer, indicating significant grant funding and collaborative research efforts. The Peifer Lab operates at the intersection of computational biology and cancer research, maintaining an interdisciplinary approach that combines bioinformatics, machine learning, and high-performance computing to address complex questions in cancer genomics. Their work has significant implications for understanding cancer evolution and developing more effective treatment strategies.
Dr. Richard H. Wiggins serves as Professor of Radiology and Imaging Sciences at the University of Utah School of Medicine, where he also holds the position of Associate Dean of Continuing Medical Education. He maintains adjunct professorships in Otolaryngology, Head and Neck Surgery, and Biomedical Informatics. His educational background includes a BA in Biochemistry from the University of Texas at Austin and an MD from the University of Texas at Houston Health Sciences Center, followed by specialized training at the University of Florida and University of Utah. Dr. Wiggins's research spans neuroradiology, biomedical informatics, and medical education innovation. His work explores advanced imaging techniques for head and neck pathologies, PET-CT applications in oncology, and the development of novel educational platforms like the RadDiscord community. He maintains particular expertise in temporal bone imaging, paragangliomas, and thyroid nodule classification systems. Analysis of his recent publications shows strong emphasis on: (1) optimizing oncologic imaging protocols, especially PET-CT applications across cancer types; (2) advancing head and neck radiology through volumetric analysis and radiomics; and (3) transforming radiology education via gamification and digital communities. His scientific honors include: Distinguished Teaching Award (Otolaryngology, University of Utah) Honored Educator Award (Radiological Society of North America) Inaugural Fellow, Academy of Health Science Educators 25th Fellow of the Society of Imaging Informatics in Medicine Fellow of the American College of Radiology He leads the Utah Head and Neck Imaging Center of Excellence, which includes an educational YouTube channel (@UHNICE). While specific grants aren't detailed, his extensive lecture record (600+ presentations) and leadership roles in professional societies like SIIM (Program Chair 2014-2020), ASHNR (Past President), and WNRS (Past President) demonstrate significant academic influence.
Li Liu is the Sir Robert Ho Tung Professor in the Department of East Asian Languages and Cultures at Stanford University. She joined the Stanford faculty in 2010, following 14 years at La Trobe University in Melbourne, Australia, where she taught archaeology and was elected a Fellow of the Academy of Humanities in Australia. Her research focuses on early China's archaeology, encompassing the Neolithic and Bronze Ages, ritual practices, cultural interactions with the Old World, domestication processes, state formation, and urban development. She holds a B.A. in Archaeology from Northwestern University (Xi'an), an M.A. in Anthropology from Temple University (Philadelphia), and a Ph.D. in Anthropology from Harvard University (1994). Dr. Liu's educational background includes degrees from prestigious institutions across multiple countries, reflecting her global academic engagement. Her work bridges archaeological methods with interdisciplinary approaches to understand societal complexity and environmental adaptation in ancient China. Notably, her contributions to understanding cultural exchanges between China and neighboring regions have been influential in East Asian Studies. Her research interests emphasize material culture analysis, settlement patterns, and the socio-political dynamics underlying early state formations. This includes investigations into ritual landscapes, agricultural practices, and urbanization processes in ancient China. Her studies often involve collaborative projects that integrate archaeological data with historical and anthropological perspectives. Dr. Liu has been recognized for her scholarly contributions, including her Fellowship in the Australian Academy of Humanities. Though her primary role is in archaeology, her Google Scholar publications reflect interdisciplinary collaborations in medical research, audio engineering, and environmental science, suggesting diverse academic engagements. In advising, she mentors students in archaeological and anthropological studies, though specific advisee names are not listed here. Her grants and funding history, while not detailed in the text, would likely support her archaeological fieldwork and interdisciplinary projects. She has contributed to the Stanford Center for East Asian Studies and affiliated programs, fostering cross-cultural research initiatives.
Dr. Megan Anderson is Associate Professor of Orthopedic Surgery at Harvard Medical School and Director of the Orthopedic Oncology Program at Boston Children's Hospital. She completed her MD at University of Florida College of Medicine (1998), residency at Cleveland Clinic Foundation, and fellowship at Harvard-affiliated hospitals (2004). Her clinical practice focuses on bone tumors and sarcomas in pediatric and young adult populations. Research examines surgical outcomes in bone cancer treatment, particularly limb-salvage techniques and reconstruction complications. Recent publications analyze cost-effectiveness of preventive interventions in metastatic bone disease. Leads multidisciplinary collaborations through the Bone and Soft Tissue Tumors Program. Active in Musculoskeletal Tumor Society and Children's Oncology Group.
Noël J-M Raynal is a Professor in the Department of Pharmacology and Physiology at the Université de Montréal and a researcher at the CHU Sainte-Justine Research Center. His expertise lies in epigenetic pharmacology of cancer and drug discovery, particularly using 3D cell culture models to study pediatric and adult cancers. He has held senior research awards from the FRQS and has led multiple projects funded by CIHR, CRSNG, and others. His work focuses on developing novel therapies targeting epigenetic modifications in cancers like neuroblastoma, sarcomas, lung cancer, and triple-negative breast cancer. Education: Ph.D. in Biology (INRS-IAF, 2008), Postdoctoral training at MD Anderson Cancer Center and Temple University. Teaching roles include courses in pharmacology and physiology. Research affiliations: GRUM (University Research Group on Medicine), Azrieli Research Center at CHU Sainte-Justine Awards: Senior FRQS Scholar (2024–2028), Junior FRQS Awards (2016–2024) Supervised 15+ students in M.Sc. and Ph.D. programs, focusing on epigenetic drug discovery and 3D tumor modeling Active in grants: Over 20 projects funded by CIHR, FRQS, and industry partnerships Research highlights include repurposing drugs like disulfiram for neuroblastoma and developing CDK9 inhibitors. His lab innovates in 3D co-culture models to better mimic tumor environments and improve drug screening accuracy.
Andrew Godwin is a Professor at the University of Kansas Medical Center , where he serves as the Chancellor’s Distinguished Chair in Biomedical Sciences and Director of Molecular Oncology in the Department of Pathology and Laboratory Medicine. He is also the Deputy Director of the NCI-designated University of Kansas Cancer Center and the Founding Director of the Kansas Institute for Precision Medicine and Biospecimen Shared Resource . Dr. Godwin is a leader in translational research and precision medicine , with a focus on molecular oncology , biomarker discovery , and genomic diagnostics . His work bridges basic and clinical science to improve cancer patient care, particularly in ovarian cancer , Ewing sarcoma , and breast cancer . He has contributed over 230 ovarian cancer-related publications and pioneered studies linking the PI3K/AKT pathway to cancer treatment targets. His research program encompasses liquid biopsies using extracellular vesicles , molecular therapeutics , companion diagnostics , and clinical trial validation . He leads the Biomarker Discovery Laboratory and has secured over $250M in extramural funding , including a $11.4M NIH grant for precision medicine initiatives. His team has developed CELLSEARCH® , the first FDA-cleared test for circulating tumor cells. Notable awards include the Dolph C. Simons, Sr. Higuchi Award (2020), Outstanding Mentorship in Pathology Award (2024), and multiple mentoring accolades from KU. He has mentored over 150 trainees across career stages and leads a multidisciplinary lab with expertise in genomics , proteomics , and bioengineering . Academic Roles: Chancellor’s Distinguished Chair in Biomedical Sciences Director, Molecular Oncology, Pathology and Laboratory Medicine Deputy Director, KU Cancer Center Founding Director, Kansas Institute for Precision Medicine Adjunct Professor, Bioengineering Program, University of Kansas Scientific Awards: KUMC Achievement Award for mentoring postdocs (2014) Chancellor’s Club Award for Research (2018) Dolph C. Simons, Sr. Higuchi Award (2020) KU Excellence in Mentoring Award (2021) Outstanding Mentorship in Pathology (2024) Key Research Themes: Extracellular vesicles as liquid biopsy tools Molecular mechanisms of sarcoma and breast cancer Genomic diagnostics and precision oncology Clinical trial biomarker validation Biospecimen repository leadership
Dr. Amarjeet Bassi is a Professor of Chemical and Biochemical Engineering in the Faculty of Engineering at Western University. He holds a Ph.D. and is a Professional Engineer (P.Eng). His research group has made significant contributions to environmental engineering, particularly in developing the world's first circulating fluidized bed ion exchange chromatography system. Dr. Bassi has established strong industry partnerships, including with Renix Inc. for commercializing his UIX technology and with Stanton Farms for phycoremediation research. Dr. Bassi's research interests focus on innovative environmental and bio-separation technologies. His work spans micro-algal applications for clean water and value recovery, integrated technologies for water refining and nutrient and energy recovery using biological systems, bio-separations, and biosensors. His research group pioneered the circulating fluidized bed ion exchange chromatography system (UIX), which is now being commercialized by Renix Inc. He has also developed significant expertise in phycoremediation, particularly for treating wastewater from dairy farms and greenhouse industries. Dr. Bassi's publication record demonstrates a strong focus on sustainable water treatment technologies, bioenergy production, and biodegradation of plastics. His recent work shows increasing attention to microplastic pollution, hydrothermal liquefaction of microalgae for bio-crude oil production, and innovative approaches to wastewater treatment using microbial systems and phycoremediation. Distinguished Speaker Award from IChE (2007) Engineering Science Prize for Outstanding Teaching at Western University (2000) SPIE Optics East Best Paper Award (2006) Dr. Bassi has graduated over 45 highly qualified personnel (PhDs, M.E.Sc and PDFs/Research Associates) and supervised more than 50 undergraduate research students. His research has been supported by significant grants from Canada Foundation for Innovation, NSERC Strategic Project grants, OMAFRA New Directions, and other funding agencies. He has served in leadership roles including President of the Canadian Society for Chemical Engineering (2014-2015) and as Associate Editor for the Canadian Journal of Chemical Engineering. Dr. Bassi leads an active research group focusing on innovative environmental technologies. His lab has developed the world's first circulating fluidized bed ion exchange chromatography system and has established successful industry partnerships, particularly with Renix Inc. for commercializing the UIX technology. His research group maintains strong collaborations with Stanton Farms for phycoremediation research and works with various industry partners on wastewater treatment and bioenergy projects.
